This patient was implanted with the argus ii device on (b)(6) 2012.This patient is participating in a post-market study of the argus ii.On (b)(6) 2014, the patient presented with endophthalmitis in the implanted eye.The patient was admitted to the hospital and was treated with systemic (iv) and local antibiotics, and systemic and local steroids.On (b)(6) 2014, the surgeon could still not see the retina on eye examination, so he injected antibiotics directly into the eye and rinsed the anterior chamber.He continued the patient on iv antibiotics.On (b)(6) 2014, the surgeon noted continued symptoms of infection in the posterior chamber.He thus decided to perform vitrectomy where he removed debris from the vitreous cavity.He filled the eye with air, left the implant in place, and injected antibiotics and steroids.On (b)(6) 2014, the surgeon reported the eye looked much better, with no hypopyon, and he planned to discharge the patient on (b)(6) 2014.On (b)(6) 2014, the surgeon saw the patient again and reported the inflammation was controlled and the cornea was clear.There were no signs of inflammation and they were further reducing the steroids.However, during that examination, the surgeon noted a recurrence of conjunctival erosion (refer to mdr report 3004081696-2014-00010).
|